fda compounding semaglutide crackdown september 2025 issued 25 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of September 2, 2025: U.S. compounding

Wegovy tablets are not currently available on the NHS

This means that it binds to the GLP-1 receptor in the brain and increases its activity, which has a number of favourable downstream effects

Stop spinning your wheels with approaches that don't work

However, not all tested GLP-1RAs have consistently demonstrated reductions in cardiovascular events, and the impact on specific cardiovascular outcomes varied among the effective drugs

For the majority of patients, the heart rate increase associated with GLP-1 receptor agonist therapy is not clinically significant and does not require treatment modification

I apologize